Sleep Disruption Among Older Men and Risk of Prostate Cancer - Lara G. Sigurdardottir; Unnur A. Valdimarsdottir; Lorelei A. Mucci; Katja Fall; Jennifer R. Rider; Eva Schernhammer; Charles A. Czeisler; Lenore Launer; Tamara Harris; Meir J. Stampfer; Vilmundur Gudnason; Steven W. Lockley
Suter A, Saller R, Riedi E, Heinrich M. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytotherapy Research. 2013; 27(2):218-26.
Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction-A prospective, randomized, double-blind, placebo-controlled clinical trial
Tribulus terrestris versus placebo in the treatment of erectile dysfunction and lower urinary tract symptoms in patients with late-onset hypogonadism: A placebo-controlled study
Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms - Fabrizio Iacono, Domenico Prezioso, Ester Illiano, Antonio Ruffo, Giuseppe Romeo & Bruno Amato
European Scientific Cooperative on Phytotherapy, ESCOP Monographs on the medical uses of plant drugs, 1st ed., ESCOP, Exeter, UK, 1997, fascicule 2
Engelmann U. et al., Therapy for benign prostatic hyperplasia with nettle liquid, Urology, 1996, 36:287-291.
Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial
N Lopatkin 1, A Sivkov, C Walther, S Schläfke, A Medvedev, J Avdeichuk, G Golubev, K Melnik, N Elenberger, U Engelmann
Safarinejad MR. Urtica dioicafor treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother, 2005; 5(4):1-11
The influence of finasteride on the development of prostate cancer
Ian M Thompson 1, Phyllis J Goodman, Catherine M Tangen, M Scott Lucia, Gary J Miller, Leslie G Ford, Michael M Lieber, R Duane Cespedes, James N Atkins, Scott M Lippman, Susie M Carlin, Anne Ryan, Connie M Szczepanek, John J Crowley, Charles A Coltman Jr
Oelke M et al. Guidelines on the treatment of non-neurogenic male LUTS.
https ://uroweb.org/gls/pdf/12Male LUTS (pdf).
Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D’Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998 Oct 1;37(2):77-83.
Agbabiaka TB et al.. Serenoa Repens (saw palmetto): a systematic review of adverse events. Drug Saf, 2009; 32:637-647
C Pavone, D Abbadessa, M L Tarantino, I Oxenius, A Laganà, A Lupo, M Rinella Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients
Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo-controlled, single-blinded study - Salvatore Sansalone
Kim TH, Jeon SH, Hahn EJ, et al. Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction. Asian J Androl. 2009
Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc status and serum testosterone levels of healthy adults. Nutrition. 1996
Abe M etal. Pharmacological relevant receptor binding characteristicsand 5 alphareductase inhibitory activities of free fatty acids contained in Saw Palmetto extract. Biol Pharm Bull. 2009 Apr; 32(4):646-50.
Arianayagam R et al. Androgen deficiency in the aging man. Aust Fam Physician, 2010; 39(10):752-755.
Avins AL et al.. A detailed safety assessment of a saw palmetto extract. Complement Ther Med, 2008; 16: 147-154.
Bae JS et al. Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signalling. J Nat Med;66(3):476-85.
Bent S et al.. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354(6):557-66.
Bertaccini A et al.. Observational database serenoa repens (DOSSER) overview, analysis and results. A multicentric SIURO (Italian Society of Oncological Urology) project. Arch Ital Urol Androl. 2012; 84(3):117-22.
Boyle P et al.. Updated meta analysis of clinical trial of serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004 Apr; 93(6):751-6.
Carlberg C et Molnar F. Current status of Vitamin D signaling and its therapeutic applications; Curr Top Med Chem, 2012 ;12(6):528-47.
Chang IH et al. A possible relationship between testosterone and lower urinary tract symptoms in men. J Urol. 2009; 182(1):215-20.
Cifti O etal.. Beneficialeffects of chrysin on there productive system of adult male rats; Andrologia, 2012; 44(3):181-6.
Costella LC et al.. Novel role of zinc in the regulation of prostate. Citrate metabolism and its implication in prostate. Prostate, 1998; 35:285-96.
De Combarieu E et al.. Furostanol saponins from tribulus terrestris, Filoterapia, 2003; 74(6) :583-91.
Debruyne F et al.. Evaluation of the clinical benefit of Permixon (Serenoa repens) in severe BPH patients. Permal study analysis. Eur Urol, 2004; 45:773-779.
Geavlete P etal. Serenoarepensextract in thetreatment of benign prostatic hyperplasia. Ther Adv Urol 2011
Iacono F et al. Observational study: daily treatment with a new compound “Tradaximinia” plus Serenoa repens for two months improved the lower urinary tract symptoms
Lopatkin N et al.. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms: Long term follow up of a placebocontrolled, double blind, multicenter trial. Int Urol Nephrol, 2007;
Vaughan CP et al. Vitamin D and lower urinary tract symptoms among US men: results from the 2005-2006 National Health and Nutrition Examination Survey. Urology, 2011; 7(6):1292-7.
Zlotta AR et al.. 2005 Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon). EurUrol; 48:269-276